REAL Patient
EXPERIENCES
Clinical preferences
The following patient experiences are based on individual accounts. Results may vary.
- Diagnosed with PI in 2011
- Started Hizentra in 2014
Treatment goals:
- Continued management of her PI symptoms
- Maintaining higher Ig trough levels and continuous infection protection
- Having more time for family and friends
Stacy’s experience with Hizentra:
- On Hizentra, she experienced more consistent Ig levels
- Now, she has continued control over her PI and more time to be a mother to her son
Individual example only; please see Prescribing Information for dosing details.
The continuous protection with Hizentra maintains that steady-state to provide me with a low risk of infection. That’s so important to me because I really want to look forward to the future.”
– Stacy
Patient advocates are compensated by CSL Behring LLC for their time and/or expenses.
- Diagnosed with PI in 2013
- Started Hizentra in 2013
- Diagnosed with PI in 2006
- Started Hizentra in 2010
Treatment goals:
- Managing their PI symptoms
- Maintaining higher Ig trough levels and continuous infection protection
- Having more time for family events and their active lifestyle
Janet and Jacob’s experience with Hizentra:
- Jacob experienced reduced symptom return between infusions, helping his school attendance stay consistent
- After witnessing his results, Janet advocated for Hizentra following her own diagnosis
- They now have continuous protection, flexibility, and time to do the things they love
Individual example only; please see Prescribing Information for dosing details.
The continuous protection we got from Hizentra was very important to us after Jacob had been on IVIg initially and he would get the really high highs and the low lows of the peaks and troughs. And so to be able to continue with a steady-state and have his levels remain consistent throughout the week was very important to us.”
– Janet
Patient advocates are compensated by CSL Behring LLC for their time and/or expenses.
- Diagnosed with PI in 1998
- Started Hizentra in 2010
History with PI:
- Would feel ill after IVIg treatments
- Experienced venous access issues resulting in multiple needle sticks for infusions
- Missed time with family due to recurring IVIg infusion appointments
Melaine’s experience with Hizentra:
- On Hizentra, she achieves consistent Ig levels and experiences fewer systemic AEs
- She regains time with her beloved family
Individual example only; please see Prescribing Information for dosing details.
After years of wrestling with treatment time and complications, we have finally found the sweet spot. With Hizentra, I get to live a life with a lower risk of infection.”
– Melaine
Patient advocates are compensated by CSL Behring LLC for their time and/or expenses.
lifestyle preferences
The following patient experiences are based on individual accounts. Results may vary.
- Diagnosed with PI in 2003
- Started Hizentra in 2010
Treatment goals:
- Managing her PI symptoms
- Increasing her comfort level during infusions
- Reducing time spent on infusions
Lynne’s experience with Hizentra:
- On Hizentra, Lynne achieved shorter infusion times
- Lynne and her husband retired to Asheville, North Carolina, where she infuses in the comfort of her home
- Prefilled syringes are easier for Lynne to handle
Individual example only; please see Prescribing Information for dosing details.
On IVIg, I travelled 3 and a half hours each month for a 6-hour infusion. I had to work my life around my infusion schedule.”
– Lynne
Patient advocates are compensated by CSL Behring LLC for their time and/or expenses.
- Diagnosed with PI in 2013
- Started Hizentra in 2015
History with PI:
- Missed time with family due to recurring hospital stays
- Desired a more flexible and convenient method of administration
- Disliked the travel time to infusion clinic
Brent’s experience with Hizentra:
- On Hizentra, he experiences a low number of days in the hospital due to infections
- The continuous protection with Hizentra gives Brent more time with his kids
- He now feels empowered to self-infuse on his terms
Individual example only; please see Prescribing Information for dosing details.
I love the prefilled syringes; it cuts out a few steps in the preparation process for my infusions. I like being able to travel with my infusion supplies. And I think, most of all, being able to infuse where and when I want* has been a game changer for me.”
– Brent
*After consultation with a healthcare professional.
Patient advocates are compensated by CSL Behring LLC for their time and/or expenses.
Abbreviations: AE, adverse event; Ig, immunoglobulin; IVIg, intravenous immunoglobulin; PI, primary immunodeficiency; SCIg, subcutaneous immunoglobulin.
References: 1. Jolles S, Rojavin MA, Lawo JP, et al. J Clin Immunol. 2018;38(8):864-875. doi:10.1007/s10875-018-0560-5 2. Jolles S, Borte M, Nelson RP Jr, et al. Clin Immunol. 2014;150(2):161-169. doi:10.1016/j.clim.2013.10.008 3. Wasserman RL, Melamed I, Nelson RP Jr, et al. Clin Pharmacokinet. 2011;50(6):405-414. doi:10.2165/11587030-000000000-00000 4. Berger M. Curr Opin Allergy Clin Immunol. 2011;11(6):532-538. doi:10.1097/ACI.0b013e32834c22da
IMPORTANT SAFETY INFORMATION
WARNING: Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin (Ig) or components of Hizentra (eg, polysorbate 80), as well as in patients with immunoglobulin A deficiency with antibodies against IgA and a history of hypersensitivity. Because Hizentra contains L-proline as stabilizer, use in patients with hyperprolinemia is contraindicated.
IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. Thrombosis may occur following treatment with Ig products, including Hizentra.
Monitor patients for aseptic meningitis syndrome (AMS), which may occur following treatment with Ig products, including Hizentra. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. In addition, monitor patients for clinical signs of hemolysis or pulmonary adverse reactions (eg, transfusion-related acute lung injury [TRALI]).
Hizentra is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
The most common adverse reactions (observed in ≥5% of study subjects) were local infusion-site reactions, as well as headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, upper respiratory tract infection, rash, pruritus, vomiting, upper abdominal pain, migraine, arthralgia, pain, fall, and nasopharyngitis.
The passive transfer of antibodies can interfere with response to live virus vaccines and lead to misinterpretation of serologic test results.
Indications
Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is indicated for:
- Treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older.
- Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
- Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy.
For subcutaneous infusion only.
Please see full Prescribing Information for Hizentra including boxed warning.
To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
Hizentra Connect℠ is a service mark of CSL Behring LLC.